JP2022537019A5 - - Google Patents
Info
- Publication number
- JP2022537019A5 JP2022537019A5 JP2021571689A JP2021571689A JP2022537019A5 JP 2022537019 A5 JP2022537019 A5 JP 2022537019A5 JP 2021571689 A JP2021571689 A JP 2021571689A JP 2021571689 A JP2021571689 A JP 2021571689A JP 2022537019 A5 JP2022537019 A5 JP 2022537019A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- binding molecule
- psma
- antigen
- bispecific antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144403A JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864999P | 2019-06-21 | 2019-06-21 | |
| US62/864,999 | 2019-06-21 | ||
| PCT/US2020/038786 WO2020257681A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144403A Division JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537019A JP2022537019A (ja) | 2022-08-23 |
| JP2022537019A5 true JP2022537019A5 (cg-RX-API-DMAC10.html) | 2023-06-21 |
| JP7743313B2 JP7743313B2 (ja) | 2025-09-24 |
Family
ID=71528054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571689A Active JP7743313B2 (ja) | 2019-06-21 | 2020-06-19 | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
| JP2024144403A Pending JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144403A Pending JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200399372A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3986933A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7743313B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220024594A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114025802B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020296181A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3139827A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL289041A (cg-RX-API-DMAC10.html) |
| MA (1) | MA56515A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2021015271A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020257681A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA202109048B (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023147784A1 (zh) * | 2022-02-07 | 2023-08-10 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd3的抗原结合分子及其医药用途 |
| WO2023224912A1 (en) * | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| JPWO2025070636A1 (cg-RX-API-DMAC10.html) * | 2023-09-26 | 2025-04-03 | ||
| CN118086511B (zh) * | 2024-04-25 | 2024-07-09 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 胃粘膜肠上皮化生亚型生物标志物folh1及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
| US11033642B2 (en) | 2014-03-19 | 2021-06-15 | Universitat Zurich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| CA2949936C (en) * | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| NZ731966A (en) * | 2014-10-16 | 2019-11-29 | Univ Melbourne | Novel imaging composition and uses thereof |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| IL304871A (en) * | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| RS67792B1 (sr) * | 2016-12-01 | 2026-03-31 | Regeneron Pharma | Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje |
| JP7125400B2 (ja) * | 2016-12-19 | 2022-08-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 標的化4-1bb(cd137)アゴニストとの併用療法 |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| AU2019315440B2 (en) * | 2018-07-30 | 2025-03-13 | Angeles Therapeutics, Inc. | Improving the efficacy and safety of adoptive cellular therapies |
-
2020
- 2020-06-19 EP EP20737787.0A patent/EP3986933A1/en active Pending
- 2020-06-19 MA MA056515A patent/MA56515A/fr unknown
- 2020-06-19 AU AU2020296181A patent/AU2020296181A1/en active Pending
- 2020-06-19 KR KR1020227001447A patent/KR20220024594A/ko active Pending
- 2020-06-19 CN CN202080045496.8A patent/CN114025802B/zh active Active
- 2020-06-19 WO PCT/US2020/038786 patent/WO2020257681A1/en not_active Ceased
- 2020-06-19 JP JP2021571689A patent/JP7743313B2/ja active Active
- 2020-06-19 CN CN202410406265.5A patent/CN118526580A/zh active Pending
- 2020-06-19 US US16/906,943 patent/US20200399372A1/en active Pending
- 2020-06-19 CA CA3139827A patent/CA3139827A1/en active Pending
- 2020-06-19 MX MX2021015271A patent/MX2021015271A/es unknown
-
2021
- 2021-11-12 ZA ZA2021/09048A patent/ZA202109048B/en unknown
- 2021-12-15 IL IL289041A patent/IL289041A/en unknown
-
2024
- 2024-08-26 JP JP2024144403A patent/JP2024164199A/ja active Pending